Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027 (NASDAQ:STLN)

Starling Oncology (STLN) reported Q3 2026 revenue of $169.8M, up 24% YoY, and adjusted EBITDA of $3.4M. The company expects 2026 revenue of $650M-$660M and adjusted EBITDA of $4M-$6M, targeting 100% capitated revenue growth in 2027, according to management.

Original reporting
Published Nov 6, 2026, 4:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$STLN
Bullish
high confidence
Mentioned
$STLN
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$STLNBullishMed
01

Why it matters

The new guidance provides a fresh data point for valuation models and may shift short-term sentiment.

02

Market read

The article offers primary earnings guidance for a listed biotech, presenting a medium‑term trading opportunity.

03

What to watch

Potential regulatory delays or clinical trial setbacks could impair the projected growth.

Relevance 7/10Novelty 7/10Timing: immediate

Background

Starling Oncology (NASDAQ:STLN) released its Q3 2026 earnings call highlights and forward guidance.

Company-level read

Ticker impact

$STLNBullishHigh confidence
Context

Starling Oncology disclosed its 2026 revenue guidance of $650M-$660M and adjusted EBITDA of $4M-$6M, plus a 100% revenue growth target for 2027.

Expected impact

potential upside as investors price in higher future revenue and profitability

Evidence & confidence

The disclosed numbers are new and materially higher than prior guidance, indicating improved outlook.

Market effects

Biotech sector may see modest uplift as a small-cap oncology firm signals strong growth.

U.S. biotech investors may adjust exposure to early-stage oncology pipelines.

Limited to investors tracking small-cap biotech earnings.

Counterpoint

Guidance may be overly optimistic given the company's early-stage pipeline; execution risk could lead to disappointment.

Key entities

  • Starling Oncology

    Biotech firm focused on oncology therapeutics.

  • Daniel Virnich

    CEO & Executive Director of Starling Oncology.

Related articles

$STLNMedAI 8/10

Oncology Institute Q3 Earnings Call Highlights

Oncology Institute (STLN) reported Q3 gross profit of $30.7M, up from $18.9M, with gross margin increasing to 18.1%. Capitated revenue rose 39.5% to $28.7M, while fee-for-service revenue fell 21% to $31.3M. The company expects 100% capitated revenue growth in 2027 and updated its 2026 outlook, including revenue of $650M-$660M and gross profit of $107M-$110M. STLN ended Q3 with $36.9M in cash.

$STLNMed

Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o

$ACRMed

ACRES Commercial Realty Corp (ACR) (Q3 2026) Earnings Call Highlights: Merger Reshapes

ACRES Commercial Realty Corp (ACR) reported Q3 2026 earnings with a GAAP net loss of $5.16 per share and EAD loss of $2.64 per share. The company completed a merger, creating a diversified platform with a $2.1B loan portfolio. Credit quality remained stable, and the company refinanced corporate debt, extending maturities. Management targets $2-$3 per share in EAD earnings but provided no specific guidance on AUM growth. One-time accounting charges and increased CECL reserves impacted results.

Med

Ferroglobe PLC (GSM) (Q3 2026) Earnings Call Highlights: Negative EBITDA, $100

Ferroglobe PLC (GSM) reported negative adjusted EBITDA of -$2M in Q3 2026, down from $30M in Q2, due to high energy costs and lower shipments. The company plans to close five plants and reduce workforce by 20%, incurring $40-60M in costs. Q4 is expected to remain challenging. The CEO discussed potential plant restarts in Venezuela and the U.S., and the company's critical materials expansion, including discussions with the U.S. government.